Skip to main content
Tech.euFundingExplorerBeta

NUCLIDIUM

Swiss clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer

Zurich, Switzerlandwww.nuclidium.com ↗
Healthtech
← All companies
Total raised
€113M
€112,556,711
Funding rounds
2
Investors
13
distinct backers
Active since
2025-07
latest 2026-05

Funding by year

EUR raised per year · 2026 YTD

Signals

High confidence
Raise-next likelihood26
base rate 48% for Series B
  • ▼ Raised very recently
  • ▼ Down/flat last round
  • ▼ Low backer re-investment
Exit likelihood14
base rate 12% (2+ rounds)
  • ▲ €100M+ raised
  • ▼ Young (<3y)

Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

2 rounds
DateStageAmountInvestors
2026-05-29Series B€29MAngelini Ventures,Aurea,Bayern Kapital,Existing investors,Kurma Growth Opportunities Fund,Neva SGR+3 moreView deal →
2025-07-11Series B€84MAngelini Ventures,Bayern Kapital,DeepTech & Climate Fonds (DTCF),Eurazeo,Existing investors,HighLight Capital+5 moreView deal →

Investors

13
Angelini VenturesAureaBayern KapitalDeepTech & Climate Fonds (DTCF)EurazeoExisting investorsHighLight CapitalKurma Growth Opportunities FundNeva SGRNeva SGR (Intesa Sanpaolo Group)NRW.BANKVIVES PartnersWellington Partners

Related news

Similar companies

same sector or country